Prostat Kanserinde <sup>225</sup>Ac-PSMA-617 ve <sup>177</sup>Lu-PSMA-617’nin Subsellüler Dozimetriye Dayalı Göreceli Etkinliği
Hwan Lee
Abstract
OBJECTIVES: Lu-PSMA-617 using subcellular dosimetry. METHODS: A 3-dimensional model of prostate cancer was constructed. For each decay, the absorbed and equivalent radiation dose to the cell nuclei was calculated. The relative efficacy per administered activity was calculated by taking into account the differences in residence time and tumor uptake. RESULTS: Lu-PSMA-617 in respective tumor sizes was at least 3,480, 4,350, and 1,230-fold higher, and possibly 11,800, 14,900, and 4,200-fold higher considering differences in tumor uptake. CONCLUSION: Lu-PSMA-617.
Topics & Concepts
MedicineRadioimmunotherapyNuclear medicineRadionuclide therapyProstate cancerCancer researchInternal medicineImmunologyCancerAntibodyMonoclonal antibodyRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and ResearchMass Spectrometry Techniques and Applications